Filing Details

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

CUSIP No. 62014P108

CUSIP No. 62014P108

CUSIP No. 62014P108

CUSIP No. 62014P108

Explanatory Note

This Amendment No. 2 (this “Amendment No. 2”) amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission on June 11, 2018, as amended by Amendment No. 1 to Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission on February 14, 2019 (as so amended, the “Schedule 13D”). Capitalized terms used in this Amendment No. 2 but not otherwise defined have the meaning given to them in the Schedule 13D.

Except as otherwise set forth herein, this Amendment No. 2 does not modify any of the information previously reported by the Reporting Persons in the Schedule 13D.

Item 2. Identity and Background.

Item 2(a) of the Schedule 13D is hereby amended as follows:

The foregoing persons are referred to herein collectively as the “Reporting Persons”.

Prior to December 31, 2019, OMCP directly held shares of Common Stock of the Issuer.  Orchestra Medical Ventures, LLC (“OMV LLC”) served as managing member to OMCP. Mr. Hochman and Mr. Sherman were the managing partners of OMV LLC. On December 31, 2019, OMCP distributed all of its securities of the Issuer on a pro rata basis to its members, for no consideration.  Consequently, as of such date, OMCP ceased to be a beneficial owner of five percent or more of the Issuer’s Common Stock, and Mr. Hochman and Mr. Sherman were no longer deemed to be beneficial owners of any such shares of Common Stock of the Issuer previously held by OMV LLC.  Mr. Hochman and Mr. Sherman received no securities of Motus GI Holdings, Inc. in the distribution of OMV LLC.

Prior to December 31, 2019, Orchestra Medical Ventures II, L.P. (“OMV II”) and Orchestra Medical Ventures II Reserve, L.P. (“OMV Reserve”) each directly held shares of Common Stock.  Orchestra Medical Ventures II GP, LLC (“OMV GP”) served as general partner to OMV II and OMV Reserve.  Mr. Hochman and Mr. Sherman were the managing members of OMV GP.  On December 31, 2019, OMV II and OMV Reserve each distributed all of their securities of the Issuer on a pro rata basis to their members, for no consideration.  Mr. Hochman was a member of OMV II and received in that distribution (a) 307 shares of Common Stock directly; (b) warrants to purchase 604 shares of Common Stock directly; (c) 298 shares of Common Stock indirectly by NSH 2008 Family Trust, of which Mr. Hochman is a co-trustee and beneficiary; and (d) warrants to purchase 3,785 shares of Common Stock indirectly by NSH 2008 Family Trust, of which Mr. Hochman is a co-trustee and beneficiary.  Mr. Sherman received no securities in the distribution of OMV II, and neither Mr. Hochman or Mr. Sherman received any securities in the distribution of OMV Reserve.

On December 31, 2019, Mr. Hochman and Mr. Sherman sold Accelerated Technologies, Inc., which owns 51,498 shares of Common Stock, to Orchestra BioMed, Inc. at a per share value of $4.49 per share, with the consideration received in the form of Orchestra BioMed, Inc. securities.  Following the disposition of Accelerated Technologies, Inc., Mr. Hochman and Mr. Sherman are no longer deemed to be beneficial owners of the securities held by Accelerated Technologies, Inc.

As of December 31, 2019, OMV II, OMCP, OMV LLC and OMV GP ceased operations in light of the distributions described above.

Item 4.  Purpose of Transaction.

Item 4 of the Schedule 13D is hereby amended to add the following information.

The information set forth under Item 2(a) of this Schedule 13D is hereby incorporated by reference.

Item 5. Interest in Securities of the Issuer.

Item 5(a)-(c) and (e) of the Schedule 13D is hereby amended and restated in its entirety as follows:

(a)-(b)  The information relating to the beneficial ownership of Common Stock by each of the Reporting Persons set forth in Rows 7 through 13 of the cover pages hereto is incorporated by reference herein. The percentages set forth in Row 13 for all cover pages filed herewith are calculated based upon a total of 28,796,017 shares of Common Stock, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 14, 2019.

(c)  The information in Item 2(a) of this Schedule 13D is hereby incorporated by reference herein.  Except as set forth in Item 2(a), the Reporting Persons and the Covered Persons effected the following transactions in the Common Stock on the dates indicated and such transactions are the only transactions in the Common Stock by the Reporting Persons and the Covered Persons in the sixty (60) days preceding the date of this Amendment No. 2 to the Schedule 13D:

(1)  On December 31, 2019, Mr. Hochman and Mr. Sherman sold Accelerated Technologies, Inc. to Orchestra BioMed, Inc. at a per share value of $4.49 per share, with the consideration received in the form of Orchestra BioMed, Inc. securities.

(2)  On February 6, 2020, Mr. Hochman was granted 20,000 Common Stock restricted stock units pursuant to the Issuer’s 2016 Equity Incentive Plan (the “2016 Plan”) and Mr. Sherman was granted 12,500 Common Stock restricted stock units pursuant to the 2016 Plan. The restricted stock units represent a contingent right to receive one share of Common Stock.  The restricted stock units vest as to 50% of the shares on February 6, 2021 and the remaining restricted stock unit shares vest on February 6, 2022.

(3) On February 6, 2020, Mr. Hochman was granted 20,000 stock options pursuant to the 2016 Plan and Mr. Sherman was granted 12,500 stock options pursuant to the 2016 Plan. The options become exercisable with respect to 50% of the shares on February 6, 2021 and the remaining options become exercisable on February 6, 2022.

(e)  On December 31, 2019, the Reporting Persons ceased to be the beneficial owner of more than five percent of the Issuer’s Common Stock.

SCHEDULE 13D/A

CUSIP No. 62014P108

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATE: February 26, 2020

---